DFW Anesthesia Professionals Blog
In anesthetic practice, glycopyrrolate is a commonly used anticholinergic medication because of its reliable anti-sialagogue effects and favorable cardiovascular and central nervous system profile. In airway management, excessive salivary and respiratory secretions may impair visualization during laryngoscopy, fiberoptic intubation, bronchoscopy, and supraglottic airway placement. A review of the anesthesia literature on glycopyrrolate to improve airway management during anesthesia demonstrates improved airway conditions, facilitation of awake airway techniques, and reduced perioperative secretion-related complications when the drug is used selectively and appropriately.
Glycopyrrolate is a quaternary ammonium anti-muscarinic agent that inhibits acetylcholine at muscarinic receptors within salivary glands and airway mucosa. Compared with atropine, glycopyrrolate minimally penetrates the blood–brain barrier, resulting in fewer central anticholinergic effects such as delirium or sedation. Intravenous administration has an onset within approximately one minute and a duration of action of two to four hours, making it useful in perioperative airway management.
Research has found strong benefits to glycopyrrolate use in awake fiberoptic intubation and airway procedures requiring optimal visualization. Excess secretions can obscure the bronchoscope lens, impair topical anesthetic distribution, and provoke coughing or laryngospasm. Pre-treatment with glycopyrrolate decreases oral and tracheobronchial secretions, improving procedural conditions and reducing the need for repeated suctioning. Administering 0.1 to 0.2 mg intravenously approximately 15 to 30 minutes before awake intubation can maximize drying effects. Clinical discussions and practice reviews consistently support this timing strategy for difficult airway management.
Glycopyrrolate may also improve airway conditions during ketamine sedation. Ketamine increases salivary and airway secretions through sympathetic and muscarinic stimulation, potentially increasing the risk of coughing, partial airway obstruction, or laryngospasm. Literature and clinician experience suggest that glycopyrrolate administration before ketamine can reduce secretion burden during spontaneous ventilation or procedural sedation cases, especially when the airway is not secured. This practice is particularly relevant in bronchoscopy, endoscopy, and awake airway management.
In pediatric anesthesia, glycopyrrolate has historically been used to decrease airway secretions during inhalational induction and airway surgery. Reduced secretions may improve visualization during direct laryngoscopy and decrease stimulation-associated reflexes. Additionally, glycopyrrolate can blunt vagally mediated bradycardia associated with airway manipulation, particularly in children. However, contemporary practice has become more selective because routine administration may produce tachycardia, xerostomia, and postoperative discomfort without clear benefit in low-risk patients.
Despite its benefits, glycopyrrolate should not be considered universally necessary for airway management. Modern volatile anesthetics, improved suction devices, and refined airway techniques have reduced dependence on routine anti-sialagogue administration. Excessive drying of secretions may create thick mucus that is difficult to clear, and anticholinergic side effects including tachyarrhythmias and urinary retention remain concerns. Recent reviews emphasize individualized use based on patient factors, airway difficulty, secretion burden, and procedural requirements rather than universal prophylaxis.
Overall, current literature supports glycopyrrolate as an important adjunct for airway management in selected anesthetic scenarios. Its ability to reduce secretions, facilitate awake airway techniques, and minimize vagal responses makes it especially valuable in difficult airway management and procedures involving shared or unprotected airways. Judicious administration tailored to patient and procedural needs remains the optimal strategy for contemporary anesthetic practice.
References
- Gallanosa A, Stevens JB, Hendrix JM, Quick J. Glycopyrrolate. In: StatPearls. StatPearls Publishing; 2025. DOI:NBK526035
- Howard J, Wigley J, Rosen G, D’mello J. Glycopyrrolate: It’s time to review. J Clin Anesth. 2017;36:51-53. DOI:34956516
- Grandhe S, Babos M. Antisialagogues. In: StatPearls. StatPearls Publishing; 2023. DOI:NBK542199
- Low J, Escobar M, Baquero S, Goldman HS, Rosen G. Glycopyrrolate and post-operative urinary retention: A narrative review. Cureus. 2020;12(11):e11379. DOI:33312781